Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa; “Kissei”) and Reborna Biosciences, Inc. (Head Office: Fujisawa, Kanagawa; Representative Director: Koji Fuji, “Reborna”) signed a research collaboration agreement on drug discovery in the field of genetic rare diseases.
Under this agreement, both companies will collaborate on drug discovery research targeting intractable genetic rare diseases using Reborna’s proprietary RNA-targeting small molecule drug discovery technology. Kissei will pay Reborna an upfront payment, research expenses, as well as milestone payments based on the progress of research, development, and sales, and royalties based on sales. In addition, Kissei will retain the right to develop and commercialize worldwide the development candidate compounds discovered through the collaboration and that meet the target criteria.
” As a drug discovery and research and development company, we are actively engaged in open innovation to realize innovative small molecule drug discovery. Through this research collaboration, we aim to accelerate the research and development of original pharmaceuticals by combining Reborna’s innovative drug discovery platform with our small molecule drug discovery capabilities, and to create drugs for intractable rare diseases.” said Mutsuo Kanzawa, CEO of Kissei.
“We are very excited for this research collaboration that fully leverages our drug discovery platform and Kissei Pharmaceutical’s robust research and development capabilities. Through open innovation with Kissei Pharmaceutical, we will continue to challenge ourselves to acquire groundbreaking insights and develop original new drugs to address key challenges in drug discovery research for rare disease.” said Koji Fuji, Representative Director of Reborna.
The consolidated business forecast for fiscal year ending March 2025 including this matter will be disclosed at the Financial Results for second quarter of fiscal year ending March 2025 to be held on November 5, 2024.
About Reborna Biosciences, Inc.
Reborna is engaged in drug discovery research for oral drugs that show disease modifying effects through normalizing RNA function by using small molecule drugs with high affinity for RNA. By making RNA that governs protein synthesis the drug discovery target, Reborna will provide drugs that offer a new approach to diseases that until now have proved difficult to treat. The company will contribute to society by providing new drugs that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn.
For more information, please visit http://rebornabiosciences.com.
